Rationale and Design of a Phase 3 Registration Trial Investigating Finerenone in Participants with CKD and Type 1 Diabetes Using a Urine Albumin-Creatinine Ratio (UACR) End Point (FINE-ONE)

Hiddo J Lambers Heerspink; Peter Rossing; Per-Henrik Groop; Helen M Colhoun; Robert Lawatscheck; Charlie Scott; Janet B McGill

Rationale and Design of a Phase 3 Registration Trial Investigating Finerenone in Participants with CKD and Type 1 Diabetes Using a Urine Albumin-Creatinine Ratio (UACR) End Point (FINE-ONE)

Hiddo J Lambers Heerspink, Peter Rossing, Per-Henrik Groop, Helen M Colhoun, Robert Lawatscheck, Charlie Scott, Janet B McGill

Steno Diabetes Center Copenhagen

Original language	English
Article number	INFO06-FR
Journal	Journal of the American Society of Nephrology
ISSN	1046-6673
Publication status	Published - 2023
Event	ASN Kidney Week 2023 - Philadelphia, United States Duration: 2 Nov 2023 → 5 Nov 2023

Conference

Conference	ASN Kidney Week 2023
Country/Territory	United States
City	Philadelphia
Period	02/11/2023 → 05/11/2023

Access to Document

https://www.asn-online.org/education/kidneyweek/2023/program-abstract.aspx?controlId=3959636

Cite this

Lambers Heerspink, H. J., Rossing, P., Groop, P.-H., Colhoun, H. M., Lawatscheck, R., Scott, C., & McGill, J. B. (2023). Rationale and Design of a Phase 3 Registration Trial Investigating Finerenone in Participants with CKD and Type 1 Diabetes Using a Urine Albumin-Creatinine Ratio (UACR) End Point (FINE-ONE). Journal of the American Society of Nephrology, Article INFO06-FR. https://www.asn-online.org/education/kidneyweek/2023/program-abstract.aspx?controlId=3959636

Rationale and Design of a Phase 3 Registration Trial Investigating Finerenone in Participants with CKD and Type 1 Diabetes Using a Urine Albumin-Creatinine Ratio (UACR) End Point (FINE-ONE). / Lambers Heerspink, Hiddo J; Rossing, Peter; Groop, Per-Henrik et al.
In: Journal of the American Society of Nephrology, 2023.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Lambers Heerspink, HJ, Rossing, P, Groop, P-H, Colhoun, HM, Lawatscheck, R, Scott, C & McGill, JB 2023, 'Rationale and Design of a Phase 3 Registration Trial Investigating Finerenone in Participants with CKD and Type 1 Diabetes Using a Urine Albumin-Creatinine Ratio (UACR) End Point (FINE-ONE)', Journal of the American Society of Nephrology. <https://www.asn-online.org/education/kidneyweek/2023/program-abstract.aspx?controlId=3959636>

@article{5c9f735960b44bc8b52be1e2fa28af3b,

title = "Rationale and Design of a Phase 3 Registration Trial Investigating Finerenone in Participants with CKD and Type 1 Diabetes Using a Urine Albumin-Creatinine Ratio (UACR) End Point (FINE-ONE)",

author = "\{Lambers Heerspink\}, \{Hiddo J\} and Peter Rossing and Per-Henrik Groop and Colhoun, \{Helen M\} and Robert Lawatscheck and Charlie Scott and McGill, \{Janet B\}",

year = "2023",

language = "English",

journal = "Journal of the American Society of Nephrology",

issn = "1046-6673",

publisher = "The American Society of Nephrology",

note = "ASN Kidney Week 2023 ; Conference date: 02-11-2023 Through 05-11-2023",

}

TY - ABST

T1 - Rationale and Design of a Phase 3 Registration Trial Investigating Finerenone in Participants with CKD and Type 1 Diabetes Using a Urine Albumin-Creatinine Ratio (UACR) End Point (FINE-ONE)

AU - Lambers Heerspink, Hiddo J

AU - Rossing, Peter

AU - Groop, Per-Henrik

AU - Colhoun, Helen M

AU - Lawatscheck, Robert

AU - Scott, Charlie

AU - McGill, Janet B

PY - 2023

Y1 - 2023

M3 - Conference abstract in journal

SN - 1046-6673

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

M1 - INFO06-FR

T2 - ASN Kidney Week 2023

Y2 - 2 November 2023 through 5 November 2023

ER -